A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides

Journal of the American Academy of Dermatology

Volumn 69, Issue 3, 2013, Pages 375-384

  Levidou, Georgia ^a   Siakantaris, Marina ^b   Papadaki, Theodora ^c   Papadavid, Evangelia ^a   Vassilakopoulos, Theodoros P ^b   Angelopoulou, Maria K ^b   Marinos, Leonidas ^c   Nikolaou, Vassiliki ^a   Economidi, Aphroditi ^a   Antoniou, Christina ^a   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

Author keywords

4E BP1; AKT; extracellular signal regulated kinase; mTOR; mycosis fungoides; NOTCH1; p70S6K; STAT3

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; PROTEIN KINASE B; STAT3 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLICULOTROPIC MYCOSIS FUNGOIDES; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SKIN BIOPSY; SKIN DEFECT; SKIN TUMOR;

4E-BP1; AKT; CANCER-SPECIFIC SURVIVAL; CSS; DFS; DISEASE-FREE SURVIVAL; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; MF; MTOR; MYCOSIS FUNGOIDES; NOTCH1; P; P70S6K; PFS; PHOSPHORYLATED; PROGRESSION-FREE SURVIVAL; STAT3;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYCOSIS FUNGOIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, NOTCH1; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84882866782     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.04.027     Document Type: Article

References (42)

1. J.T. Edinger, B.Z. Clark, B.E. Pucevich, L.J. Geskin, and S.H. Swerdlow CD30 expression and proliferative fraction in nontransformed mycosis fungoides Am J Surg Pathol 33 2009 1860 1868
2. M.J. Riemenschneider, R.A. Betensky, S.M. Pasedag, and D.N. Louis AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling Cancer Res 66 2006 5618 5623
3. B.D. Manning, A.R. Tee, M.N. Logsdon, J. Blenis, and L.C. Cantley Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway Mol Cell 10 2002 151 162
4. H. Pópulo, J.M. Lopes, and P. Soares The mTOR signaling pathway in human cancer Int J Mol Sci 13 2012 1886 1918
5. K. Tomita, M. Hattori, E. Nakamura, S. Nakanishi, N. Minato, and R. Kageyama The bHLH gene Hes1 is essential for expansion of early T cell precursors Genes Dev 13 1999 1203 1210
6. T. Palomero, M. Dominguez, and A.A. Ferrando The role of the PTEN/AKT pathway in NOTCH1-induced leukemia Cell Cycle 7 2008 965 970
7. E.C. Holland, N. Sonenberg, P.P. Pandolfi, and G. Thomas Signaling control of mRNA translation in cancer pathogenesis Oncogene 23 2004 3138 3144
8. K. Yokogami, S. Wakisaka, J. Avruch, and S.A. Reeves Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR Curr Biol 10 2000 47 50
9. T.J. Mitchell, and S. John Signal transducer and activator of transcription (STAT) signaling and T-cell lymphomas Immunology 114 2005 301 312
10. C.L. Berger, D. Hanlon, D. Kanada, M. Dhodapkar, V. Lombillo, and N. Wang The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells Blood 99 2002 2929 2939
11. E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, and R. Knobler Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood 110 2007 1713 1722
12. F. Rojo, L. Najera, J. Lirola, J. Jiménez, M. Guzmán, and M.D. Sabadell 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis Clin Cancer Res 13 2007 81 89
13. P. Korkolopoulou, G. Levidou, E.A. El-Habr, C. Piperi, C. Adamopoulos, and V. Samaras Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas Histopathology 61 2012 293 305
14. J.H. Schatz Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies Curr Oncol Rep 13 2011 398 406
15. A. Fasolo, and C. Sessa Current and future directions in mammalian target of rapamycin inhibitors development Expert Opin Investig Drugs 20 2011 381 394
16. S.M. Smith Targeting mTOR in mantle cell lymphoma: current and future directions Best Pract Res Clin Haematol 25 2012 175 183
17. G. Hess, S.M. Smith, A. Berkenblit, and B. Coiffier Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes Semin Oncol 36 Suppl 2009 S37 S45
18. M. Marzec, X. Liu, M. Wysocka, A.H. Rook, N. Odum, and M.A. Wasik Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells PLoS One 6 2011 e24849
19. W.Y. Shi, D. Xiao, L. Wang, L.H. Dong, Z.X. Yan, and Z.X. Shen Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy Cell Death Dis 3 2012 e275
20. M. Kremer, K. Sliva, C.D. Klemke, and B.S. Schnierle Cutaneous T-cell lymphoma cells are sensitive to rapamycin Exp Dermatol 19 2010 800 805
21. + T lymphocytes Blood 111 2008 2181 2189
22. M. Fornaro, J. Plescia, S. Chheang, G. Tallini, Y.M. Zhu, and M. King Fibronectin protects prostate cancer cells from tumor necrosis factor-Alpha-induced apoptosis via the AKT/survivin pathway J Biol Chem 278 2003 50402 50411
23. Y. Dobashi, S. Suzuki, H. Matsubara, M. Kimura, S. Endo, and A. Ooi Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas Cancer 115 2009 107 118
24. S.M. Johnson, P. Gulhati, B.A. Rampy, Y. Han, P.G. Rychahou, and H.Q. Doan Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer J Am Coll Surg 210 2010 767 778
25. L. Schultz, R. Albadine, J. Hicks, S. Jadallah, A.M. DeMarzo, and Y.B. Chen Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
26. P. Korkolopoulou, G. Levidou, E.A. Trigka, N. Prekete, M. Karlou, and I. Thymara A comprehensive immunohistochemical and molecular approach to pi3k/akt/mtor pathway in bladder carcinoma BJU Int 110 2012 E1237 E1248
27. C.H. Sun, Y.H. Chang, and C.C. Pan Activation of the PI3K/Akt/mTOR pathway correlates with tumor progression and reduced survival in patients with urothelial carcinoma of the urinary bladder Histopathology 58 2011 1054 1063
28. J. Castellvi, A. Garcia, F. Rojo, C. Ruiz-Marcellan, A. Gil, and J. Baselga Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer Cancer 107 2006 1801 1811
29. X. Wang, A. Beugnet, M. Murakami, S. Yamanaka, and C.G. Proud Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins Mol Cell Biol 25 2005 2558 2572
30. M. Mizoguchi, R.A. Betensky, T.T. Batchelor, D.C. Bernay, D.N. Louis, and C.L. Nutt Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival J Neuropathol Exp Neurol 65 2006 1181 1188
31. + lymphoproliferative disorders: a new therapeutic approach? Br J Dermatol 163 2010 781 788
32. F. Jundt, I. Anagnostopoulos, R. Förster, S. Mathas, H. Stein, and B. Dörken Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma Blood 99 2002 3398 3403
33. M. Reedijk, S. Odorcic, L. Chang, H. Zhang, N. Miller, and D.R. McCready High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival Cancer Res 65 2005 8530 8537
34. K. Balint, M. Xiao, C.C. Pinnix, A. Soma, I. Veres, and I. Juhasz Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression J Clin Invest 115 2005 3166 3176
35. F. Jundt, K.S. Pröbsting, I. Anagnostopoulos, G. Muehlinghaus, M. Chatterjee, and S. Mathas Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells Blood 103 2004 3511 3515
36. E. Rosati, R. Sabatini, G. Rampino, A. Tabilio, M. Di Ianni, and K. Fettucciari Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells Blood 113 2009 856 865
37. S. Tohda, and N. Nara Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells Leuk Lymphoma 42 2001 467 472
38. Q. Zhou, Z. Deng, Y. Zhu, H. Long, S. Zhang, and J. Zhao mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis Med Oncol 27 2010 1239 1245
39. E. Galanis, J.C. Buckner, M.J. Maurer, J.I. Kreisberg, K. Ballman, and J. Boni Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 23 2005 5294 5304
40. A.M. Martelli, C. Evangelisti, M.Y. Follo, G. Ramazzotti, M. Fini, and R. Giardino Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells Curr Med Chem 18 2011 2715 2726
41. N.S. Agar, E. Wedgeworth, S. Crichton, T.J. Mitchell, M. Cox, and S. Ferreira Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer staging proposal J Clin Oncol 28 2010 4730 4739
42. C. Muniesa, T. Estrach, R.M. Pujol, F. Gallardo, P. Garcia-Muret, and J. Climent Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases J Am Acad Dermatol 62 2010 418 426